Stocks To Keep Your Eyes On: Newmont Mining (NYSE:NEM), Starbucks (NASDAQ:SBUX), Stanley Black & Decker (NYSE:SWK), Celgene Corporation (NASDAQ:CELG)

Investment analysts at Deutsche Bank boosted their target price on shares of Newmont Mining Corp (NYSE:NEM), from $19.00 to $21.00 in a note issued to investors on Monday,AnalystRatingsNetwork reports. The firm currently has a “hold” rating on the stock. Newmont Mining Corp (NYSE:NEM), shares after opening at $23.74 moved to $23.90 on last trade day and at the end of the day closed at $23.54. Company price to sales ratio in past twelve months was calculated as 1.41 and price to cash ratio as 7.18. Newmont Mining Corp (NYSE:NEM), showed a negative weekly performance of 5.04%.

Starbucks Corp. (NASDAQ:SBUX) had its price objective hosited by Barclays from $78.00 to $81.00 in a report released on Tuesday, Analyst Ratings Network.com reports. Barclays currently has an equal weight rating on the stock. Starbucks Corporation (NASDAQ:SBUX), shares fell 0.90% in last trading session and ended the day on $70.15. Starbucks Corporation (NASDAQ:SBUX), return on equity ratio is recorded as 2.30% and its return on assets is 1.20%. Starbucks Corporation (NASDAQ:SBUX), yearly performance is 23.16%.

Stanley Black & Decker, Inc. (NYSE:SWK), declared a quarterly dividend on Tuesday, April 15th, Stock Ratings News reports. Investors of record on Wednesday, June 4th will be given a dividend of 0.50 per share on Tuesday, June 17th. This represents a $2.00 dividend on an annualized basis and a yield of 2.55%. Stanley Black & Decker, Inc. (NYSE:SWK), shares moved up 0.54% in last trading session and was closed at $81.92, while trading in range of $ 81.45 – 82.30. Stanley Black & Decker, Inc. (NYSE:SWK), year to date (YTD) performance is 2.14%.

Shares of Celgene Corporation (NASDAQ:CELG), closed up 6.58% on nearly 6 million shares traded. The stock was one of the biggest gainers on the NASDAQ. Public documents for the pre-trial Markman hearing appear to favor the company over Natco, the generic drugmaker challenging some of Celgene’s Revlimid patents. This is according to the Street’s Adam Feuerstein reports. Celgene Corporation (NASDAQ:CELG), weekly performance is 1.09%. On last trading day company shares ended up $141.15. Celgene Corporation (NASDAQ:CELG), distance from 50-day simple moving average (SMA50) is -6.92%. Analysts mean target Price for the company is $193.50.